ArticleCancer gene therapy2007
Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection.
Article in Cancer gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Electroporation-mediated novel albumin-fused Flt3L DNA delivery promotes cDC1-associated anticancer immunity.Gene therapy · 2025Article
- FLT3L-induced virtual memory CD8 T cells engage the immune system against tumors.Journal of biomedical science · 2024Article
- FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis.Cell reports. Medicine · 2023Article
- Flt3L therapy increases the abundance of Treg-promoting CCR7Frontiers in immunology · 2023Article
- Acute effects of FLT3L treatment on T cells in intact mice.Scientific reports · 2022Article
- Immune Modulation by Myeloid-Derived Suppressor Cells in Diabetic Kidney Disease.International journal of molecular sciences · 2022Review
- Review
- Phenotype, development, and biological function of myeloid-derived suppressor cells.Oncoimmunology · 2016Review
- Cutting edge: Flt3 ligand mediates STAT3-independent expansion but STAT3-dependent activation of myeloid-derived suppressor cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model.Laboratory investigation; a journal of technical methods and pathology · 2014Article
- History of myeloid-derived suppressor cells.Nature reviews. Cancer · 2013Review
- Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives.Immunological investigations · 2012Review
- Negative regulation of myeloid-derived suppressor cells in cancer.Immunological investigations · 2012Review
- Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance.Frontiers in immunology · 2012Article
- IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Attenuation of vaccinia virus by the expression of human Flt3 ligand.Virology journal · 2010Article
- Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.Cancer immunology, immunotherapy : CII · 2010Article
- A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.Immunological reviews · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cell (DC) expansion is regulated by the hematopoietic growth factor fms-like tyrosine kinase 3 ligand (Flt3L). DCs are critical to the control of tumor growth and metastasis, and there is a positive correlation between intratumoral DC infiltration and clinical outcome. In this report, we first demonstrate that single intravenous (i.v.) injections of adenovirus (Adv)-Flt3L significantly increased splenic dendritic, B, T and natural killer (NK) cell numbers in both normal and mammary tumor-bearing mice. In contrast, the numbers of DCs and T cells infiltrating the tumors were not increased. Consistent with the minimal effect on immune cell infiltration, i.v. Adv-Flt3L injections had no therapeutic activity against orthotopic mammary tumors. In addition, we noted tumor and Adv-Flt3L expansion of Gr1(+)CD11b(+) immature myeloid suppressor cells (IMSCs), which may inhibit the therapeutic efficacy of Adv-Flt3L-expanded DCs.
Indexed as
Identifiers
17235356What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.